HC Wainwright Increases Delcath Systems (NASDAQ:DCTH) Price Target to $20.00

Delcath Systems (NASDAQ:DCTH) had its target price upped by analysts at HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 319.29% from the company’s current price.

Delcath Systems Trading Down 6.3 %

Shares of DCTH stock opened at $4.77 on Wednesday. Delcath Systems has a 52-week low of $2.25 and a 52-week high of $7.99. The company has a 50-day simple moving average of $4.36 and a two-hundred day simple moving average of $3.85. The company has a market capitalization of $105.18 million, a price-to-earnings ratio of -1.61 and a beta of 0.51. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.11 and a current ratio of 3.30.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Tuesday, March 26th. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.19. Delcath Systems had a negative net margin of 2,308.86% and a negative return on equity of 1,007.65%. The firm had revenue of $0.54 million during the quarter, compared to the consensus estimate of $0.48 million. During the same period in the prior year, the firm earned ($0.86) EPS. Research analysts anticipate that Delcath Systems will post -1.9 EPS for the current fiscal year.

Insider Activity

In other Delcath Systems news, Director Gil Aharon purchased 26,882 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The shares were bought at an average cost of $3.72 per share, for a total transaction of $100,001.04. Following the purchase, the director now owns 1,069,710 shares of the company’s stock, valued at approximately $3,979,321.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 21.10% of the company’s stock.

Institutional Trading of Delcath Systems

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. lifted its stake in Delcath Systems by 19.7% in the 4th quarter. Vanguard Group Inc. now owns 522,008 shares of the company’s stock worth $2,172,000 after purchasing an additional 85,948 shares in the last quarter. ADAR1 Capital Management LLC purchased a new stake in Delcath Systems in the 4th quarter worth approximately $962,000. Northern Trust Corp lifted its stake in Delcath Systems by 82.7% in the 4th quarter. Northern Trust Corp now owns 60,667 shares of the company’s stock worth $252,000 after purchasing an additional 27,458 shares in the last quarter. AIGH Capital Management LLC purchased a new stake in Delcath Systems in the 4th quarter worth approximately $4,918,000. Finally, Worth Venture Partners LLC purchased a new stake in Delcath Systems in the 4th quarter worth approximately $1,224,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.